Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

Vertex Pharmaceuticals remains on hold with a $494 price target from Stifel analysts after discussions about its chronic pain ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.68% to $432.00 Tuesday, on what proved to be an all-around mixed trading ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 15 years ago, it would be worth $11,812.35 today based on ...

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. Vertex's business and prospects remain attractive.

Vertex Pharmaceuticals is making waves with its new pain treatment, Journavx, which is experiencing a prescription growth ...

Vertex Pharmaceuticals is diversifying its already strong lineup of medicines. Axsome Therapeutics has multiple clinical and ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Entrada Therapeutics, Inc.’s TRDA share price has surged by 5.86%, which has investors questioning if this is right time to sell.

CRISPR Therapeutics, whose CEO is Samarth Kulkarni, and Vertex Pharmaceuticals earned the first U.S. Food and Drug ...